Astellas Pharma (OTCMKTS:ALPMY) Stock Crosses Below 200-Day Moving Average – Here’s Why

Shares of Astellas Pharma Inc. (OTCMKTS:ALPMY) passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $10.77 and traded as low as $9.64. Astellas Pharma shares last traded at $9.71, with a volume of 89,294 shares changing hands.

Astellas Pharma Stock Performance

The company has a current ratio of 1.04, a quick ratio of 0.80 and a debt-to-equity ratio of 0.39. The company’s fifty day moving average is $9.62 and its 200 day moving average is $10.77. The company has a market cap of $17.57 billion, a P/E ratio of -44.13 and a beta of 0.34.

Astellas Pharma (OTCMKTS:ALPMY) last released its earnings results on Tuesday, February 4th. The company reported $0.30 EPS for the quarter. Astellas Pharma had a negative net margin of 3.10% and a positive return on equity of 13.69%. As a group, equities analysts predict that Astellas Pharma Inc. will post 0.42 earnings per share for the current fiscal year.

Astellas Pharma Company Profile

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.